Final overall survival and safety analyses of the phase III PSMAfore trial of [¹⁷⁷Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

In PSMAfore, [¹⁷⁷Lu]Lu-PSMA-617 (¹⁷⁷Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC), with a favourable safety profile, versus a change in androgen receptor pathway inhibitor (ARPI). We report the final overall survival (OS) analysis and updated safety data.

Patients and methods

PSMAfore (NCT04689828) was an open-label, international, phase III trial. Patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who had experienced disease progression once on a previous ARPI and were candidates for ARPI change were randomized 1 : 1 to ¹⁷⁷Lu-PSMA-617 or ARPI change to abiraterone or enzalutamide. Crossover from ARPI cha

SUBMITTER: Fizazi K 

PROVIDER: S-EPMC12399216 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature